Lars F.
- Country
- Germany
- Department
- "Studiengesellschaft BSF UG (haftungsbeschränkt) Gastroenterology"
Research Overview
- Phase 2 Randomized Study of LY4395089 Combined with Mirikizumab Versus Mirikizumab Alone in Adults with Moderately to Severely Active Crohn’s Disease
- Phase 3 Randomized Double‑Blind Study Evaluating Efficacy and Safety of JNJ‑78934804 Combination Therapy versus Guselkumab in Moderately to Severely Active Crohn’s Disease
- Phase 3 Randomized Double‑Blind Trial of JNJ‑78934804 Combination Therapy vs Guselkumab in Moderately to Severely Active Ulcerative Colitis
Data & Insights
Has run more than one trial at 391 of 629 partner sites.
Specializations
Inflammatory Bowel Disease Management
The investigator specializes in treating moderate to severe inflammatory bowel conditions, with particular focus on innovative therapeutic approaches for both ulcerative colitis and Crohn's disease.
- Novel Biologic Therapies
- Combination Treatment Strategies
- Long-term Disease Management
Research interests include evaluating emerging treatments for intestinal inflammation and their long-term efficacy profiles.
Gastrointestinal Oncology
Focuses on advanced treatments for gastric and gastroesophageal junction adenocarcinoma and colorectal cancer, particularly in stage II and III disease states.
- Targeted Cancer Therapies
- Post-surgical Treatment Strategies
- Precision Medicine Approaches
Specializes in evaluating innovative therapeutic interventions for gastrointestinal malignancies.
Specialized Digestive Disorders
Investigates treatments for complex digestive conditions, including non-responsive celiac disease and fibrostenotic Crohn's disease.
- Immune System Modulation
- Novel Treatment Pathways
- Disease-Specific Interventions
Explores innovative therapeutic approaches for treatment-resistant digestive disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.